8-K current report · filed Nov 12, 2026

Prime Medicine, Inc. (PRME) 8-K Current Report: November 12, 2026

Item 1.01PRME overview

Short answer

Prime Medicine, Inc. (PRME) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $125.0 million base equity offering: 35,714,286 shares priced at $3.50 each.

Prime Medicine, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $125.0 million base equity offering: 35,714,286 shares priced at $3.50 each
  • Additional 5,357,142-share underwriter option, potentially increasing gross proceeds
  • Approximately $134.7 million expected net proceeds if the option is fully exercised
  • Funding targeted primarily at Wilson disease, alpha-1 antitrypsin deficiency and other R&D programs
  • Material shareholder dilution, with closing expected around November 12, 2026 subject to customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Prime Medicine, Inc. 8-K filings

Get the next PRME 8-K as it lands

Follow PRME for push alerts, or ask the research agent what this filing means.